BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
Running, not enrolling · Phase 1
Conditions studied: Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma, MDM2 Gene Amplification, Myxoid Liposarcoma, CIC-Rearranged Sarcoma
In brief
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma. The name of the study drug used in this research study is: -BTX-A51 (a type of kinase inhibitor)
Key facts
- Study ID
- NCT06414434
- Run by
- Michael Wagner, MD
- People needed
- 24
- Starts
- 2024-09-30
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-07-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Study participants must have histologically-confirmed metastatic and/or recurrent liposarcoma (limited to the subtypes of well-differentiated and/or dedifferentiated liposarcoma, which are associated with MDM2 amplifications), or myxoid liposarcoma, or CIC-rearranged sarcoma.
- ECOG performance status ≤2
- Adequate organ and marrow function as defined by the following metrics resulted within 7 days of study enrollment:
- WBC >3000/mm3
- Platelets >75,000μl
- ANC >1500μl
- Hgb >9g/dl
- Creatinine <1.5 x ULN or measured CrCl of >60ml/m2/1.73 m2
- Total bilirubin <2 x ULN
- AST/ALT <3 x ULN
- Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non- nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as
- ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.
- Patients must have recovered from toxicity related to prior therapy to grade <=1 (defined by CTCAE v5.0) (except alopecia and neuropathy, or immunotherapy related hypothyroidism)
- As the effect of this study drug on the developing human fetus is not known, women of child-bearing potential and men must agree to use at least 2 methods of contraception (abstinence; hormonal or barrier method of birth control) for the study and at least 2 months after completion.
- Female patient of childbearing potential has a negative serum pregnancy test within 7 days of study enrollment.
- Ability to understand and the willingness to sign a written informed consent document.
- Age ≥18 years
- Patients must have completed all prior anti-cancer treatment for liposarcoma, including radiation, ≥ 14 days prior to registration.
You may not qualify if…
- Patient with current evidence of active and uncontrolled infection, NYHA Class III-IV CHF, documented Child's class B-C cirrhosis, or uncontrolled medical disease which in the opinion of the investigator or the sponsor could compromise safety and/or assessment of efficacy.
- Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV); subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative PCR result before enrollment; those who are PCR positive will be excluded.
- Major surgical procedure or open surgical biopsy within 28 days of first dose of study drug
- Active central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity. Subject with known CNS metastases that are treated and stable (without evidence of CNS toxicity) and are not requiring systemic steroids are allowed to be enrolled.
- Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Myocardial infarction within 12 months of screening
- Use of any other concurrent investigational agents or anticancer agents, excluding hormonal therapy for breast or prostate cancer
- Pregnant women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BTX- A51, breastfeeding should be discontinued if the mother is treated with BTX-A51.
- Inability to swallow pills or inadequate GI absorption in the opinion of the treating investigator.
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.